How effective is Verzenio + aromatase inhibitor (AI)?
Verzenio was studied in combination with an aromatase inhibitor as initial endocrine-based therapy in 493 postmenopausal women with newly diagnosed hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced or metastatic breast cancer (MBC). 328 patients were treated with Verzenio + aromatase inhibitor and 165 were treated with an aromatase inhibitor alone.
Clinical trials are still ongoing to determine if there is an overall survival benefit with Verzenio.
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea.
At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids.
Taking Verzenio + AI
The recommended dose of Verzenio in combination with an AI is 150 mg by mouth twice a day, taken once in the morning and once at night.
You will receive 4 individual packs, each one containing your dose of 150-mg tablets for 7 days. Each of these packs includes 14 individual 150-mg tablets.
- Multiple tablet strengths (50 mg, 100 mg, and 150 mg) allow your doctor to make dose adjustments based on your tolerance
- If you need to reduce your dose due to tolerability, Verzenio is approved to be dosed as low as 50 mg twice daily, as directed by your doctor
- No matter what dose you are prescribed, you will take 1 tablet, 2 times a day, unless your doctor tells you otherwise
If your doctor prescribes:
Live longer without cancer getting worse
Verzenio + an AI delayed disease progression for over 2 years (a median of 28.2 months) vs 14.8 months with an AI alone